iBio (IBIO) Short-Term Debt issuances (2023 - 2025)

iBio's (IBIO) quarterly Short-Term Debt issuances came in at $105000.0 in Q3 2025, up 115.2% on a QoQ basis from -$691000.0 in Q2 2024.

iBio (IBIO) Short-Term Debt issuances (2023 - 2025) Analysis & Trends

iBio (IBIO) has 3 years of Short-Term Debt issuances data on file, last reported at $105000.0 in Q3 2025.

On a quarterly basis, Short-Term Debt issuances changed N/A year-over-year to $105000.0 in Q3 2025; TTM through Sep 2025 was $105000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $204000.0, changed N/A from the prior year.
Short-Term Debt issuances for Q3 2025 stood at $105000.0, up from -$691000.0 in the prior quarter.
Over the last five years, Short-Term Debt issuances for IBIO reached as high as $691000.0 in Q1 2024 and fell as low as -$691000.0 in Q2 2024.
Historically, Short-Term Debt issuances has averaged $77250.0 across 3 years, with a median of $154500.0 in 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Short-Term Debt issuances (Qtr)
1	Oculis Holding AG	67,042.03 Bn	67,041.74 Bn	-	-
2	Nanobiotix	1,908.00 Bn	1,907.94 Bn	-	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-	102,000.00
4	BeOne Medicines	472.89 Bn	468.10 Bn	1.35 Bn	58.20 Mn
5	Vertex Pharmaceuticals	122.12 Bn	114.87 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	70.04 Bn	61.29 Bn	3.31 Bn	-
7	Belite Bio	62.68 Bn	62.68 Bn	-	-
8	Argenx Se	55.90 Bn	50.72 Bn	1.41 Bn	-
9	Alnylam Pharmaceuticals	37.47 Bn	34.46 Bn	959.66 Mn	-
10	iBio	166.84 Mn	166.84 Mn	-	-

Download Data